AbbVie Wins Analyst Confidence With Q2 Beat, Diverse Portfolio Fuels Long-Term Growth Expectations
AbbVie Wins Analyst Confidence With Q2 Beat, Diverse Portfolio Fuels Long-Term Growth Expectations
On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter adjusted EPS of $2.65, down 8.9% year over year, beating the consensus of $2.57.
艾伯維公司（NYSE:ABBV）週四發佈了第二季度每股收益2.65美元，同比下降8.9％，超過2.57美元的共識。
Net revenues reached $14.46 billion, up 4.3%, beating the consensus of $14.03 billion. Sales were up 5.6% on an operational basis.
淨收入達到144.6億美元，上漲了4.3％，超過了140.3億美元的共識。銷售收入在運營基礎上上漲了5.6％。
Cantor Fitzgerald writes that quality 2Q24 earnings results support a positive investment thesis and increase confidence that growth will accelerate in 2025+. This high single-digit, above-market growth in 2025+ is not fully reflected in the stock's valuation yet.
Cantor Fitzgerald指出，優質的2Q24收益結果支持積極的投資主題，並增加了未來增長加速的信心。2025年及以後高單位數字的市場增長還沒有完全反映在股票估值中。
The analyst reiterates the Overweight rating, with a price target of $200.
分析師重申超配（Overweight）評級並給出200美元的價格目標。
Truist Securities maintains the Buy rating and increases the price target from 195 to $210. The analyst sees strong performance across AbbVie's diversified portfolio and potential for ongoing growth into the end of the decade.
Truist Securities保持買入評級，並將價格目標從195美元上調至210美元。分析師認爲AbbVie的多元化產品組合表現強勁，潛力十足，可以持續增長到2020年代末。
Despite IRA's impact on Humira and Imbruvica, AbbVie continues to be set up for long-term growth led by key growth drivers Skyrizi and Rinvoq and ongoing momentum for the current portfolio of products and pipeline.
儘管IRA對Humira和Imbruvica產生影響，AbbVie仍將持續通過關鍵增長驅動器Skyrizi和Rinvoq以及目前產品組合和產品線的持續發展而獲得長期增長。
Despite expectations for continued strong performance in Immunology, Goldman Sachs notes that Skyrizi and Rinvoq will maintain their growth momentum, driven by new-to-brand prescription (NBRx) trends indicating the potential for increased market share in inflammatory bowel disease (IBD) and the significant role of mechanism-of-action switching, particularly among CVS/biosimilar patients.
儘管市場對免疫學仍有強勁的表現預期，高盛指出，Skyrizi和Rinvoq將保持增長動力，驅動力來自新品牌處方（NBRx）趨勢，表明在炎症性腸病（IBD）領域可能會增加市場份額，機制作用的轉換在CVS /生物類似物患者中尤其重要。
This treatment pathway, which is advantageous for AbbVie, is not fully reflected in current forecasts.
這種治療途徑對艾伯維公司非常有利，但目前的預測並未完全反映這一點。
AbbVie's long-term growth outlook remains strong. Despite challenges in the aesthetics sector, management has assured that the Cerevel acquisition will close soon, possibly next week.
AbbVie的長期增長前景仍然強勁。儘管美容業面臨一些挑戰，管理層已經保證Cerevel的收購很快會結束，可能會在下週進行。
This development addresses a significant uncertainty and positions the company for several potential high-impact data catalysts in the second half of 2024 and into 2025.
這一進展解決了一個重大不確定因素，併爲公司在2024年下半年和2025年產生了幾個潛在的高影響數據觸發器，爲未來奠定了基礎。
Goldman Sachs increases the price target from $190 to $200, reiterating the Buy rating.
高盛將評級從買入提高到增持，並將價格目標從190美元提高到200美元。
Needham writes that AbbVie reported a strong bounceback in the aesthetics business during the second quarter but reported some unexpected softness in the U.S. market.
Needham寫道，艾伯維公司在第二季度的美容業務出現強勁反彈，但在美國市場報告了一些意外的疲軟。
AbbVie reported lower-than-expected procedure growth and made some slight downward adjustments to their aesthetics guidance due to slower-than-expected near-term growth.
AbbVie報告了低於預期的醫療增長，並由於短期增長速度放緩而對他們的美容業務指導進行了輕微下調。
Price Action: ABBV stock is up 2.08% at $185.96 at last check Friday.
股票ABBV在上週五收盤時上漲2.08％至185.96美元。
Photo via Shutterstock
圖片來自shutterstock。
- AbbVie Appeals To Supreme Court Over Attorney-Client Privilege In 'Long-Standing' AndroGel Case.
- 艾伯維公司就長期的AndroGel案件向最高法院尋求律師-客戶特權。